These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 21849527)

  • 1. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors.
    Leal LF; Mermejo LM; Ramalho LZ; Martinelli CE; Yunes JA; Seidinger AL; Mastellaro MJ; Cardinalli IA; Brandalise SR; Moreira AC; Tone LG; Scrideli CA; Castro M; Antonini SR
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3106-14. PubMed ID: 21849527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
    Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
    Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas.
    Jucá CEB; Colli LM; Martins CS; Campanini ML; Paixão B; Jucá RV; Saggioro FP; de Oliveira RS; Moreira AC; Machado HR; Neder L; Antonini SR; de Castro M
    Horm Metab Res; 2018 Jul; 50(7):575-581. PubMed ID: 29625497
    [No Abstract]   [Full Text] [Related]  

  • 5. Unraveling the expression of the oncogene YAP1, a Wnt/beta-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients.
    Abduch RH; Carolina Bueno A; Leal LF; Cavalcanti MM; Gomes DC; Brandalise SR; Masterallo MJ; Yunes JA; Martinelli CE; Tone LG; Tucci S; Molina CA; Ramalho FS; Moreira AC; Cardinalli IA; Scrideli CA; Ramalho LN; de Castro M; Antonini SR
    Oncotarget; 2016 Dec; 7(51):84634-84644. PubMed ID: 27705928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered expression of noncanonical Wnt pathway genes in paediatric and adult adrenocortical tumours.
    Mermejo LM; Leal LF; Colli LM; Fragoso MC; Latronico AC; Tone LG; Scrideli CA; Tucci S; Martinelli CE; Yunes JA; Mastellaro MJ; Seidinger AL; Brandalise SR; Moreira AC; Ramalho LN; Antonini SR; Castro M
    Clin Endocrinol (Oxf); 2014 Oct; 81(4):503-10. PubMed ID: 24717047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
    Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
    Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
    Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
    Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation.
    Schweigert A; Fischer C; Mayr D; von Schweinitz D; Kappler R; Hubertus J
    Pediatr Surg Int; 2016 Dec; 32(12):1141-1146. PubMed ID: 27679509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
    Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
    Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secreted frizzled related protein 1 regulates Wnt signaling for BMP2 induced chondrocyte differentiation.
    Gaur T; Rich L; Lengner CJ; Hussain S; Trevant B; Ayers D; Stein JL; Bodine PV; Komm BS; Stein GS; Lian JB
    J Cell Physiol; 2006 Jul; 208(1):87-96. PubMed ID: 16575902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological analysis of β-catenin and Axin-1 in solid pseudopapillary neoplasms of the pancreas.
    Huang SC; Ng KF; Yeh TS; Chang HC; Su CY; Chen TC
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S438-46. PubMed ID: 21769465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors.
    Chapman A; Durand J; Ouadi L; Bourdeau I
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1477-81. PubMed ID: 21733995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas.
    Götze S; Wolter M; Reifenberger G; Müller O; Sievers S
    Int J Cancer; 2010 Jun; 126(11):2584-93. PubMed ID: 19847810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular activation of Wnt signaling through epigenetic dysregulation of Wnt inhibitory factor-1 (Wif-1) is associated with pathogenesis of adrenocortical tumor.
    Mitsui Y; Yasumoto H; Nagami T; Hiraki M; Arichi N; Ishikawa N; Araki A; Maruyama R; Tanaka Y; Dahiya R; Shiina H
    Oncotarget; 2014 Apr; 5(8):2198-207. PubMed ID: 24755523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
    Brown TC; Nicolson NG; Korah R; Carling T
    J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.